Clinical Trial Update: Nab-pacliatxel Plus Gemcitabine in Korean Patients With Metastatic Pancreatic Ductal Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update examining nab-paclitaxel plus gemcitabine in Korean patients with metastatic pancreatic ductal adenocarcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Samsung Medical Center | Conditions: Pancreatic Ductal Adenocarcinoma | Phase 2 | Status: COMPLETED